A citation-based method for searching scientific literature

Carol Aghajanian, Stephanie V Blank, Barbara A Goff, Patricia L Judson, Michael G Teneriello, Amreen Husain, Mika A Sovak, Jing Yi, Lawrence R Nycum. J Clin Oncol 2012
Times Cited: 781







List of co-cited articles
510 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Rucaparib: a novel PARP inhibitor for BRCA advanced ovarian cancer.
Ilaria Colombo, Stephanie Lheureux, Amit Manulal Oza. Drug Des Devel Ther 2018
12
16


PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression.
Shiping Jiao, Weiya Xia, Hirohito Yamaguchi, Yongkun Wei, Mei-Kuang Chen, Jung-Mao Hsu, Jennifer L Hsu, Wen-Hsuan Yu, Yi Du, Heng-Huan Lee,[...]. Clin Cancer Res 2017
368
2

Targeting the ATR/CHK1 Axis with PARP Inhibition Results in Tumor Regression in BRCA-Mutant Ovarian Cancer Models.
Hyoung Kim, Erin George, Ryan Ragland, Stavros Rafail, Rugang Zhang, Clemens Krepler, Mark Morgan, Meenhard Herlyn, Eric Brown, Fiona Simpkins. Clin Cancer Res 2017
122
2

FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy.
Geoffrey Kim, Gwynn Ison, Amy E McKee, Hui Zhang, Shenghui Tang, Thomas Gwise, Rajeshwari Sridhara, Eunice Lee, Abraham Tzou, Reena Philip,[...]. Clin Cancer Res 2015
296
2

Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.
Jennifer K Litton, Hope S Rugo, Johannes Ettl, Sara A Hurvitz, Anthony Gonçalves, Kyung-Hun Lee, Louis Fehrenbacher, Rinat Yerushalmi, Lida A Mina, Miguel Martin,[...]. N Engl J Med 2018
602
2

Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity.
Ilirjana Bajrami, Jessica R Frankum, Asha Konde, Rowan E Miller, Farah L Rehman, Rachel Brough, James Campbell, David Sims, Rumana Rafiq, Sean Hooper,[...]. Cancer Res 2014
184
2

Apoptosis is augmented in high-grade serous ovarian cancer by the combined inhibition of Bcl-2/Bcl-xL and PARP.
Takuhei Yokoyama, Elise C Kohn, Ethan Brill, Jung-Min Lee. Int J Oncol 2017
15
13

Rucaparib: First Global Approval.
Yahiya Y Syed. Drugs 2017
34
5

Role of the folate receptor in ovarian cancer treatment: evidence, mechanism, and clinical implications.
Ignace B Vergote, Christian Marth, Robert L Coleman. Cancer Metastasis Rev 2015
80
2


Progression-free survival by local investigator versus independent central review: comparative analysis of the AGO-OVAR16 Trial.
Anne Floquet, Ignace Vergote, Nicoletta Colombo, Bent Fiane, Bradley J Monk, Alexander Reinthaller, Paula Calvert, Thomas J Herzog, Werner Meier, Jae-Weon Kim,[...]. Gynecol Oncol 2015
20
10

The NCI-MATCH trial and precision medicine in gynecologic cancers.
Lisa Barroilhet, Ursula Matulonis. Gynecol Oncol 2018
24
8

Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer.
S Percy Ivy, Joyce F Liu, Jung-Min Lee, Ursula A Matulonis, Elise C Kohn. Expert Opin Investig Drugs 2016
28
7


Epidemiology of epithelial ovarian cancer.
Penelope M Webb, Susan J Jordan. Best Pract Res Clin Obstet Gynaecol 2017
274
2

Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumors.
Kathleen N Moore, Hossein Borghaei, David M O'Malley, Woondong Jeong, Shelly M Seward, Todd M Bauer, Raymond P Perez, Ursula A Matulonis, Kelli L Running, Xiaoyan Zhang,[...]. Cancer 2017
41
4

The search for biomarkers to direct antiangiogenic treatment in epithelial ovarian cancer.
Angeles Alvarez Secord, Andrew B Nixon, Herbert I Hurwitz. Gynecol Oncol 2014
24
8

FORWARD I: a Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer.
Kathleen N Moore, Ignace Vergote, Ana Oaknin, Nicoletta Colombo, Susana Banerjee, Amit Oza, Patricia Pautier, Karim Malek, Michael J Birrer. Future Oncol 2018
35
5


Ovarian Cancers: Genetic Abnormalities, Tumor Heterogeneity and Progression, Clonal Evolution and Cancer Stem Cells.
Ugo Testa, Eleonora Petrucci, Luca Pasquini, Germana Castelli, Elvira Pelosi. Medicines (Basel) 2018
68
2

Efficacy and safety results from OCTAVIA, a single-arm phase II study evaluating front-line bevacizumab, carboplatin and weekly paclitaxel for ovarian cancer.
Antonio Gonzalez-Martin, Laurence Gladieff, Bengt Tholander, Daniel Stroyakovsky, Martin Gore, Giovanni Scambia, Nadezhda Kovalenko, Ana Oaknin, Julian Perez Ronco, Ulrich Freudensprung,[...]. Eur J Cancer 2013
30
6


Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): A subgroup analysis of the MITO-16A-MaNGO OV2A phase 4 trial.
Gennaro Daniele, Domenica Lorusso, Giovanni Scambia, Sabrina C Cecere, Maria Ornella Nicoletto, Enrico Breda, Nicoletta Colombo, Grazia Artioli, Lucia Cannella, Giovanni Lo Re,[...]. Gynecol Oncol 2017
22
9

VEGF, VEGFRs expressions and activated STATs in ovarian epithelial carcinoma.
Huaizeng Chen, Dafeng Ye, Xing Xie, Bingya Chen, Weiguo Lu. Gynecol Oncol 2004
105
2

Phase II study of bevacizumab with liposomal doxorubicin for patients with platinum- and taxane-resistant ovarian cancer.
C F Verschraegen, S Czok, C Y Muller, L Boyd, S J Lee, T Rutledge, S Blank, B Pothuri, S Eberhardt, F Muggia. Ann Oncol 2012
32
6



Measurements of adiposity as clinical biomarkers for first-line bevacizumab-based chemotherapy in epithelial ovarian cancer.
Katrina N Slaughter, Theresa Thai, Shayla Penaroza, Doris M Benbrook, Elangovan Thavathiru, Kai Ding, Tina Nelson, D Scott McMeekin, Kathleen N Moore. Gynecol Oncol 2014
33
6

Phase II study of irinotecan in combination with bevacizumab in recurrent ovarian cancer.
Fernanda Musa, Bhavana Pothuri, Stephanie V Blank, Huichung T Ling, James L Speyer, John Curtin, Leslie Boyd, Xiaochun Li, Judith D Goldberg, Franco Muggia,[...]. Gynecol Oncol 2017
19
10

Biomarkers in the development of anti-angiogenic therapies for ovarian cancer.
Fharat A Raja, Jane M Hook, Jonathan A Ledermann. Cancer Treat Rev 2012
15
13

A phase II trial of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube.
Thomas J Herzog, Bradley J Monk, Peter G Rose, Patricia Braly, Jeffrey F Hines, Maria C Bell, Robert M Wenham, Angeles Alvarez Secord, Lynda D Roman, Mark H Einstein,[...]. Gynecol Oncol 2014
15
13

Phase II study of bevacizumab and pemetrexed for recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer.
Andrea R Hagemann, Akiva P Novetsky, Israel Zighelboim, Feng Gao, L Stewart Massad, Premal H Thaker, Matthew A Powell, David G Mutch, Jason D Wright. Gynecol Oncol 2013
18
11

Which factors predict bowel complications in patients with recurrent epithelial ovarian cancer being treated with bevacizumab?
D L Richardson, F J Backes, J D Hurt, L G Seamon, L J Copeland, J M Fowler, D E Cohn, D M O'Malley. Gynecol Oncol 2010
34
5

Bevacizumab with or after chemotherapy for platinum-resistant recurrent ovarian cancer: exploratory analyses of the AURELIA trial.
A Bamias, E Gibbs, C Khoon Lee, L Davies, M Dimopoulos, F Zagouri, A-S Veillard, J Kosse, A Santaballa, M R Mirza,[...]. Ann Oncol 2017
12
16

Prognostic and predictive effects of primary versus secondary platinum resistance for bevacizumab treatment for platinum-resistant ovarian cancer in the AURELIA trial.
F Trillsch, S Mahner, F Hilpert, L Davies, E García-Martínez, G Kristensen, A Savarese, P Vuylsteke, M Los, F Zagouri,[...]. Ann Oncol 2016
13
15


Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer.
Ernest S Han, Robert A Burger, Kathleen M Darcy, Michael W Sill, Leslie M Randall, Dana Chase, Basmina Parmakhtiar, Bradley J Monk, Benjamin E Greer, Patrick Connelly,[...]. Gynecol Oncol 2010
50
4



The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer.
Seiji Mabuchi, Hiromasa Kuroda, Ryoko Takahashi, Tomoyuki Sasano. Gynecol Oncol 2015
238
2

Immunotherapy opportunities in ovarian cancer.
Christina S Chu, Sarah H Kim, Carl H June, George Coukos. Expert Rev Anticancer Ther 2008
47
4

Optimizing treatment in recurrent epithelial ovarian cancer.
Giacomo Corrado, Vanda Salutari, Eleonora Palluzzi, Maria Grazia Distefano, Giovanni Scambia, Gabriella Ferrandina. Expert Rev Anticancer Ther 2017
57
3

An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience.
Kate E Oliver, William E Brady, Michael Birrer, David M Gershenson, Gini Fleming, Larry J Copeland, Krishnansu Tewari, Peter A Argenta, Robert S Mannel, Angeles Alvarez Secord,[...]. Gynecol Oncol 2017
35
5

Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer.
Gottfried E Konecny, Chen Wang, Habib Hamidi, Boris Winterhoff, Kimberly R Kalli, Judy Dering, Charles Ginther, Hsiao-Wang Chen, Sean Dowdy, William Cliby,[...]. J Natl Cancer Inst 2014
197
2


Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy.
Razvan Cristescu, Robin Mogg, Mark Ayers, Andrew Albright, Erin Murphy, Jennifer Yearley, Xinwei Sher, Xiao Qiao Liu, Hongchao Lu, Michael Nebozhyn,[...]. Science 2018
655
2

Biomarker Assessment of HR Deficiency, Tumor BRCA1/2 Mutations, and CCNE1 Copy Number in Ovarian Cancer: Associations with Clinical Outcome Following Platinum Monotherapy.
Euan A Stronach, James Paul, Kirsten M Timms, Elisha Hughes, Krystal Brown, Christopher Neff, Michael Perry, Alexander Gutin, Mona El-Bahrawy, Jennifer H Steel,[...]. Mol Cancer Res 2018
34
5

Phase II trial of nintedanib in patients with bevacizumab-resistant recurrent epithelial ovarian, tubal, and peritoneal cancer.
Angeles Alvarez Secord, Michael McCollum, Brittany A Davidson, Gloria Broadwater, Robert Squatrito, Laura J Havrilesky, Anne C Gabel, Mark D Starr, J Chris Brady, Andrew B Nixon,[...]. Gynecol Oncol 2019
11
18

Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance).
Andrew B Nixon, Herbert Pang, Mark D Starr, Paula N Friedman, Monica M Bertagnolli, Hedy L Kindler, Richard M Goldberg, Alan P Venook, Herbert I Hurwitz. Clin Cancer Res 2013
76
2


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.